Cadrenal Therapeutics, Inc.

New Filing
CIK: 0001937993·Biotechnology·DELAWARE·Filed: Dec 31, 2025
Total Offering

$4,396,329

Amount Sold

$4,396,329

Investors

4

First Sale

Dec 16, 2025

Offering Details

Type
Option to Acquire, Security to be Acquired
Exemptions
Rule 506(b)

Related Persons

NameRole
QUANG X. PHAM
Executive Officer, Director
MATTHEW K. SZOT
Executive Officer
JEFFREY COLE
Executive Officer
JAMES J. FERGUSON
Executive Officer
STEVEN ZELENKOFSKE
Director
GLYNN WILSON
Director
JOHN R. MURPHY
Director
LEE S. GOLDEN
Director

Company

Cadrenal Therapeutics, Inc.

822 A1A NORTH

PONTE VEDRA, FL, 32082

(904) 900-0701

SEC Filing

0001213900-25-127129

View on SEC EDGAR

Want deeper insights?

Sign up for free to search all filings, track companies, and set up alerts.

Sign Up Free